pika covid-19 vaccine (cho cell, s-protein)

Vaccineexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0

Earliest trial started Oct 18, 2021 (NCT05305300)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05463419Phase 2/Phase 3 (Phase 3)Oct 6, 2022Yisheng Biopharma
NCT05305300Phase 1Oct 18, 2021Yisheng Biopharma
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Yisheng BiopharmaFor profit2222021
1 organizations
Page 1 / 1